Mar 26, 2009 - Dyax Corp. announced today that it has received a complete response letter from the U.S. FDA pertaining to the Company's Biologic License Application (BLA) for DX-88 (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE).
The details can be read here.
No comments:
Post a Comment